Therapeutic Asset Ratings
12,938 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
TRIMETAPHAN
Multiple System Atrophy
Vanderbilt University
P1
CC
(46)
tt125-802
Squamous Cell Lung Carcinoma
TOLREMO therapeutics AG
P1
CC
(46)
Tvb-2640 -
Metabolic Dysfunction-Associated Steatohepatitis
Sagimet Biosciences Inc.
P1
CC
(46)
ub-312
Multiple System Atrophy
NYU Langone Health
P1
CC
(46)
Ucar T-Cell
Autoimmune Disease
The Children's Hospital of Zhejiang University School of Medicine
P1
CC
(46)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells
Plasma Cell Myeloma
Elvira Umyarova
P1
CC
(46)
vb10.neo
Solid Tumors, Adult
Nykode Therapeutics ASA
P1
CC
(46)
Veliparib
Cancer
National Cancer Institute (NCI)
P1
CC
(46)
Veliparib
Cancer Of Unknown Primary Site
National Cancer Institute (NCI)
P1
CC
(46)
(+)-VINCRISTINE
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
(+)-VINCRISTINE
Advanced or Metastatic Solid Tumor
Taiho Pharmaceutical Co., Ltd.
P1
CC
(46)
(+)-VINCRISTINE
Juvenile Myelomonocytic Leukemia
Johns Hopkins All Children's Hospital
P1
CC
(46)
VINCRISTINE SULFATE
Chronic Myelomonocytic Leukemia (CMML)
Prelude Therapeutics
P1
CC
(46)
vk2735
Metabolic Dysfunction-Associated Steatohepatitis
Viking Therapeutics, Inc.
P1
CC
(46)
Vorinostat
Juvenile Myelomonocytic Leukemia
Johns Hopkins All Children's Hospital
P1
CC
(46)
Vorinostat
Wilms Tumor
New York Medical College
P1
CC
(46)
vx-634
Alpha 1-Antitrypsin Deficiency
Vertex Pharmaceuticals Incorporated
P1
CC
(46)
WARFARIN
Metabolic Dysfunction-Associated Steatohepatitis
Altimmune, Inc.
P1
CC
(46)
WARFARIN
Obesity Disorder
Beijing QL Biopharmaceutical Co.,Ltd
P1
CC
(46)
WARFARIN
Tuberous Sclerosis Complex (TSC)
GRIN Therapeutics, Inc.
P1
CC
(46)
y-3 for
Tolerability
Neurodawn Pharmaceutical Co., Ltd.
P1
CC
(46)
YH 001
Cancer
Eucure (Beijing) Biopharma Co., Ltd
P1
CC
(46)
Zanubrutinib
Chronic Myelomonocytic Leukemia
Prelude Therapeutics
P1
CC
(46)
Zimberelimab
Head And Neck Squamous Cell Carcinoma
Arcus Biosciences, Inc.
P1
CC
(46)
Zn-C3
Ovarian Carcinoma
OHSU Knight Cancer Institute
P1
CC
(46)
Showing 776 to 800 of 12,938 assets
Previous
Page 32 of 518
Next